Business
Mirum Pharmaceuticals to Showcase LIVMARLI Data at ESPGHAN Annual Meeting
Seven abstracts accepted including four oral presentations Phase 3 MARCH PFIC data selected as one of highest scoring abstracts and will be presented during
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\n\nSeven abstracts accepted including four oral presentations\n\n\n\nPhase 3 MARCH PFIC data selected as one of highest scoring abstracts and will be presented during the plenary session on May 18\n\n\n\nRISE study evaluating LIVMARLI in infants with ALGS or PFIC included among highest scoring posters\n\n\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will present data at the upcoming 55th Annual European Society for Pediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting, taking place May 17-20, 2023, in Vienna, Austria. The company will present data from its LIVMARLI® (maralixibat) oral solution clinical studies in Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC).\n\n\nData from Mirum’s studies of LIVMARLI® (maralixibat) oral solution include oral and poster presentations:\n\n\nOral presentations\n\n\nAbstract 477 – H-O027: Efficacy and safety of maralixibat in patients with progressive familial intrahepatic cholestasis (MARCH-PFIC): A randomized placebo-controlled Phase 3 study\nThursday, May 18, 2023 - 11:45am-1:15pm CET, Plenary Session, Highest Scoring Abstracts, Hall A\nPresented at 1:02pm CET by Professor Richard J. Thompson, King’s College, London\n\n\nAbstract 468- H-O029: Maralixibat improves cholestatic pruritus and bile acids in children with FIC1: Data from the MARCH-PFIC trial\nFriday, May 19, 2023 – 12:00-1:00pm - Parallel Session: Hepatology-Abstract Session 02, Hall G\nPresented at 12:00pm CET by Professor Richard J. Thompson, King’s College, London\n\n\nAbstract 472 – H-O010: Maralixibat improves xanthomas and hypercholesterolemia in children with Alagille syndrome: an integrated analysis from two clinical trials\nFriday, May 19, 2023 – 12:00-1:00pm - Parallel Session: Hepatology-Abstract Session 02, Hall G\nPresented at 12:32pm CET Dr. Brett Hoskins, The Johns Hopkins Hospital School of Medicine, Baltimore, Maryland\n\n\nAbstract 463 – H-O008: Real-world safety experience in patients with Alagille syndrome treated with maralixibat\nFriday, May 19, 2023 – 12:00-1:00pm, Parallel Session: Hepatology-Abstracts 02, Hall G\nPresented at 12:40pm CET by Dr. Regino P. Gonzalez-Peralta, AdventHealth for Children and AdventHealth Transplant Institute, Orlando, Florida\n\n\nPoster Presentations\n\n\nAbstract...